PULMONX CORPORATION Financials Pulmonx Corporation
Equities
LUNG
US7458481014
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.32 USD | +4.60% |
|
+5.79% | -26.90% |
| May. 01 | Earnings Flash (LUNG) PULMONX CORPORATION Posts Q1 Revenue $18.9M, vs. Street Est of $17.9M | MT |
| May. 01 | Transcript : Pulmonx Corporation, Q1 2024 Earnings Call, May 01, 2024 |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,462 | 1,181 | 315.4 | 488.4 | 345.8 | - | - |
| Enterprise Value (EV) 1 | 2,257 | 1,019 | 198.6 | 488.4 | 345.8 | 345.8 | 345.8 |
| P/E ratio | -21.8 x | -23.8 x | -5.3 x | -7.97 x | -5.32 x | -5.71 x | -7.19 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 75.2 x | 24.4 x | 5.88 x | 7.11 x | 4.17 x | 3.5 x | 2.93 x |
| EV / Revenue | 75.2 x | 24.4 x | 5.88 x | 7.11 x | 4.17 x | 3.5 x | 2.93 x |
| EV / EBITDA | -77.3 x | -25.4 x | -5.52 x | -8.09 x | -6 x | -6.46 x | -8.02 x |
| EV / FCF | -78 x | - | - | -12.7 x | -17.8 x | - | - |
| FCF Yield | -1.28% | - | - | -7.87% | -5.61% | - | - |
| Price to Book | 10.9 x | 6.13 x | 2.06 x | - | - | - | - |
| Nbr of stocks (in thousands) | 35,669 | 36,839 | 37,409 | 38,308 | 38,816 | - | - |
| Reference price 2 | 69.02 | 32.07 | 8.430 | 12.75 | 8.910 | 8.910 | 8.910 |
| Announcement Date | 3/2/21 | 2/23/22 | 2/22/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 32.73 | 48.42 | 53.66 | 68.68 | 82.92 | 98.71 | 118.2 |
| EBITDA 1 | -31.85 | -46.44 | -57.12 | -60.39 | -57.68 | -53.53 | -43.13 |
| EBIT 1 | -32.33 | -47.3 | -58.64 | -61.94 | -66.21 | -62.19 | -50.73 |
| Operating Margin | -98.77% | -97.7% | -109.27% | -90.19% | -79.85% | -63.01% | -42.94% |
| Earnings before Tax (EBT) 1 | -32.02 | -48.32 | -58.57 | -60.27 | -64.47 | -60.83 | -49.35 |
| Net income 1 | -32.23 | -48.66 | -58.92 | -60.84 | -65.04 | -61.41 | -49.93 |
| Net margin | -98.47% | -100.51% | -109.8% | -88.6% | -78.44% | -62.21% | -42.25% |
| EPS 2 | -3.160 | -1.350 | -1.590 | -1.600 | -1.675 | -1.562 | -1.239 |
| Free Cash Flow 1 | -31.54 | - | - | -38.42 | -19.4 | - | - |
| FCF margin | -96.37% | - | - | -55.94% | -23.4% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 3/2/21 | 2/23/22 | 2/22/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 13.71 | 10.78 | 13.95 | 13.5 | 15.42 | 14.54 | 17.19 | 17.67 | 19.28 | 18.85 | 20.2 | 20.55 | 23.34 | 22.45 | 24.61 |
| EBITDA 1 | -11.99 | -15.3 | -14.04 | -13.55 | -14.24 | -15.96 | -16.03 | -14.76 | -13.63 | -14.11 | -14.29 | -14.67 | -16.13 | -10.52 | -8.188 |
| EBIT 1 | -12.37 | -15.67 | -14.41 | -13.93 | -14.63 | -16.4 | -16.44 | -15.18 | -13.92 | -14.54 | -16.53 | -16.88 | -18.25 | -14.58 | -15.86 |
| Operating Margin | -90.21% | -145.28% | -103.3% | -103.18% | -94.83% | -112.83% | -95.61% | -85.9% | -72.2% | -77.1% | -81.82% | -82.12% | -78.19% | -64.94% | -64.43% |
| Earnings before Tax (EBT) 1 | -12.85 | -15.76 | -14.6 | -14.17 | -14.04 | -15.74 | -16.06 | -14.84 | -13.64 | -13.56 | -16.32 | -16.61 | -17.99 | -14.02 | -15.3 |
| Net income 1 | -13.01 | -15.83 | -14.64 | -14.17 | -14.28 | -15.86 | -16.2 | -14.9 | -13.89 | -13.75 | -16.4 | -16.69 | -18.09 | -14.02 | -15.3 |
| Net margin | -94.88% | -146.76% | -104.95% | -104.96% | -92.6% | -109.12% | -94.19% | -84.33% | -72.04% | -72.92% | -81.17% | -81.24% | -77.5% | -62.47% | -62.17% |
| EPS 2 | -0.3500 | -0.4300 | -0.4000 | -0.3800 | -0.3800 | -0.4200 | -0.4300 | -0.3900 | -0.3600 | -0.3600 | -0.4241 | -0.4270 | -0.4633 | -0.3612 | -0.3900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/23/22 | 5/3/22 | 8/2/22 | 11/3/22 | 2/22/23 | 5/2/23 | 8/2/23 | 10/30/23 | 2/21/24 | 5/1/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | 205 | 163 | 117 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -31.5 | - | - | -38.4 | -19.4 | - | - |
| ROE (net income / shareholders' equity) | -183% | -23.2% | -27.5% | -44.7% | -62.1% | -80.4% | -61.9% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | 6.340 | 5.230 | 4.100 | - | - | - | - |
| Cash Flow per Share | -3.010 | - | -1.220 | - | - | - | - |
| Capex | 0.91 | - | - | 0.81 | - | - | - |
| Capex / Sales | 2.78% | - | - | 1.18% | - | - | - |
| Announcement Date | 3/2/21 | 2/23/22 | 2/22/23 | 2/21/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.91
USD
Average target price
15.4
USD
Spread / Average Target
+72.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.90% | 346M | |
| +73.63% | 12.43B | |
| -18.62% | 8.09B | |
| -0.90% | 6.12B | |
| +14.66% | 5.59B | |
| -14.69% | 5.47B | |
| +39.93% | 5.23B | |
| -16.51% | 4.1B | |
| -27.62% | 2.65B | |
| +1.36% | 1.99B |
- Stock Market
- Equities
- LUNG Stock
- Financials Pulmonx Corporation
